Why did 2496.HK stock drop so much pre-market on 24 Mar 2026?

The sharp fall to HKD 4.05 reflected thin liquidity, technical selling, and renewed concerns over trial timelines and cash burn; volume was 2,400 versus an average of 3,719, amplifying price moves.

What is Meyka AI's forecast for 2496.HK stock?

Meyka AI's forecast model projects **HKD 7.09** at 12 months, implying **74.90%** upside from HKD 4.05 today; forecasts are model-based projections and not guarantees.

What are the main risks for investors in 2496.HK stock?

Key risks include negative EPS of -0.46, strained liquidity with current ratio 0.92, negative free cash flow per share of -0.16, and trial or regulatory setbacks that can trigger binary downside.

Does Meyka AI recommend buying 2496.HK stock now?

Meyka AI rates 2496.HK at 64.13/100 (Grade B, HOLD); that reflects mixed fundamentals and sector upside but it is not a recommendation. Conduct your own research before trading.

HK Stocks

2496.HK Wuhan YZY Biopharma HKSE down 30.89% pre-market 24 Mar 2026: catalysts ahead

ByDanny Kontos March 24, 2026March 24, 2026

2496.HK stock plunged 30.89% pre-market on 24 Mar 2026 to HKD 4.05, marking the largest one-day drop in recent sessions. The move follows heavy selling after a run of disappointing short-term results and lower trading liquidity, with volume at 2,400 versus a 3,719 average. Investors in Hong Kong (HKSE) are re-pricing Wuhan YZY Biopharma Co Ltd (2496.HK) as clinical and cash-flow questions return to the foreground, while biotech sector weakness adds pressure.